% greater relative reduction in body weight 1 †
PATIENTS ACHIEVED ≥20 % body weight reduction with Mounjaro vs ~ 1 in 4 with Wegovy 1 ‡
SUPERIOR REDUCTION in waist circumference with Mounjaro vs Wegovy 1 §
SURMOUNT-5
Mounjaro vs Wegovy
WEIGHT
UP TO
47
% greater relative reduction in body weight 1 †
† At 72 weeks, patients taking Mounjaro MTD( maximum tolerated dose; 10 mg or 15 mg) experienced superior mean percentage body weight reduction from baseline of-20.2 % vs-13.7 % in those taking Wegovy MTD( 1.7 mg or 2.4 mg) using the TRE( 47 % relative reduction), or-21.6 % vs-15.4 %, respectively, using the EE( 40 % relative reduction), p < 0.001 for both, adjusted for multiplicity, mITT population. 1
~ 1 in 2
PATIENTS ACHIEVED ≥20 % body weight reduction with Mounjaro vs ~ 1 in 4 with Wegovy 1 ‡
SUPERIOR REDUCTION in waist circumference with Mounjaro vs Wegovy 1 §
The overall safety profile of Mounjaro in SURMOUNT-5 was similar to previously reported SURMOUNT trials 1, 2 ¶
‡ At 72 weeks, a body weight reduction target of ≥20 % from baseline was achieved by 48.4 % of patients taking Mounjaro MTD( 10 mg or 15 mg) vs 27.3 % in those taking Wegovy MTD( 1.7 mg or 2.4 mg), p < 0.001, TRE, imputed data, adjusted for multiplicity. 1
§
Change in waist circumference from baseline to week 72( key secondary endpoint):-18.4 cm vs-13.0 cm( TRE);-20.0 cm vs-14.7 cm( EE); p < 0.001 vs Wegovy for both, adjusted for multiplicity. 1
¶
The study was not powered to compare the safety and tolerability of Mounjaro and the safety and tolerability of Wegovy. 1
Scan the QR code to learn more about Mounjaro
PBS Information: Mounjaro ®( tirzepatide) is not listed on the PBS.
Please refer to the full Product Information before prescribing. Product Information can be accessed at www. lilly. com. au / en / products, or by scanning the QR code, or on request by calling 1800 454 559.
This medicinal product is subject to additional monitoring in Australia due to approval of an extension of indications. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems.
© 2025 Eli Lilly Australia Pty Ltd. Mounjaro ® is a registered trademark of Eli Lilly and Company. Wegovy ® is a registered trademark of Novo Nordisk A / S. Eli Lilly Australia Pty Ltd. ABN 39 000 233 992. Level 9, 60 Margaret St, Sydney NSW 2000. Telephone: 1800 454 559. Date of preparation: May 2025. PP-TR-AU-0646. 2008098.